The IDH1 R132H mutation is both a strong prognostic predictor and a diagnostic hallmark of gliomas and therefore has major clinical relevance. Here, we developed a new technique to detect the IDH1 R132H mutation in the plasma of patients with glioma.
The identification of a reliable biomarker in accessible bodily fluids 1 would be useful for diagnostic, prognostic, and follow-up in glioma patients. DNA containing somatic mutations are highly tumor-specific and thus provide optimal markers. 2 Circulating tumor DNA, as evidenced by the presence of a specific mutation, is mostly degraded and has a median size of 150 -250 bp. 3 Circulating tumor DNA has been detected in several types of cancers including breast, colorectal, lung, pancreatic, and melanoma. 4, 5 A few studies have reported gross genomic alterations such as loss of heterozygosity (LOH) or epigenetic changes in circulating tumor DNA extracted from the blood of patients with gliomas. 6 -8 However, the detection of glioma-specific mutations in the plasma of patients represents a much more specific and reliable marker, but this has not been evaluated thus far. The "ideal" mutation should be frequent, occur at a specific genomic site, and have a strong diagnostic, prognostic, or predictive value. The IDH1 mutation fulfills these conditions 9 : 1) it is involved in 40% of all gliomas, 2) the R132H substitution represents 95% of the mutations in this gene, 3) the IDH1 mutation is a glioma-specific diagnostic marker, and 4) the IDH1 gene mutation is one of the most powerful independent prognostic factors described in patients with gliomas. 10 -13 In this study, we combined coamplification at lower denaturation temperature PCR (COLD PCR) 14 and digital PCR 15 to detect the IDH1 R132H mutation in free circulating DNA, and estimate the diagnostic accuracy according to tumor volume and contrast enhancement.
METHODS Patients. Patients treated at the Pitié Salpêtrière
Neuro-Oncology Department were selected prospectively, from March 2010 to March 2011, according to the following criteria: 1) histologic glioma diagnosis according to WHO classification, 2) IDH1 status previously determined by Sanger sequencing of tumor DNA, and 3) written, informed consent before enrollment in the study. Healthy controls were recruited from within the laboratory and hospital staff. Blood samples were collected during the standard clinical follow-up of patients. The study has been approved by the local Human Investigations Committee in accordance with the tenets of the Declaration of Helsinki.
Tumor volume evaluation on MRI scans. All MRI were performed on a 1.5-T scan within a median of 7 days from blood sampling and included pre-and postcontrast enhanced T1weighted images in multiple planes, fluid-attenuated inversion recovery (FLAIR), or T2-weighted sequences. We estimated the tumor volume by the modified ellipsoid volume equation as follows: (A ϫ B ϫ C)/2, where A, B, and C represent the 3 largest orthogonal diameters of the lesion, which was measured digitally or manually with calipers on MRI films. We measured tumor volume by T2/FLAIR hyperintensity in the low-grade gliomas and by contrast enhancement volume in the highgrade gliomas.
DNA extraction. Blood samples were collected in EDTAcoated tubes and centrifuged immediately at 1,000 g for 15 minutes at 4°C. The plasma was collected, centrifuged again at 10,000 g for 5 minutes at room temperature, aliquoted, and stored at Ϫ80°C until use. A 50 L solution was eluted from 4 mL of plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen). The sample was then treated with 20 mg/mL RNase A (Invitrogen) to remove RNA contamination, and the DNA was purified using NucleoSpin Extract II (Macherey Nagel). An aliquot was run on a 2100 Bioanalyzer (Agilent Technologies) using the Agilent High Sensitivity DNA kit to determine DNA size and DNA concentration.
Detection of IDH1 R132H mutation by digital PCR in plasma samples. Detection of the IDH1 R132H mutation in plasma samples was performed following a 2-step procedure: selective mutant DNA amplification by COLD PCR and further characterization by digital PCR.
The plasma DNA was first amplified by a run of COLD PCR on a LightCycler 480 (Roche Applied Science) as previously described. 16 Briefly, the cycling parameters were as follows: 96°C for 10 minutes, 20 cycles of 95°C for 15 seconds and 60°C for 30 seconds, and 30 cycles of 81°C for 15 seconds and 60°C for 30 seconds. The COLD PCR assays contained the following final reagent concentrations: 1X LightCycler 480 HRM Master Mix (Roche Applied Science), 0.25 M forward and reverse primers (Invitrogen), 3 mM MgCl 2 , and 5 L DNA (table e-1 on the Neurology ® Web site at www.neurology.org). The PCR amplicons were diluted at 1/1,000,000 with distilled water and then characterized by digital PCR.
For digital PCR, PCR products of each sample were assayed on a 1,536 well plate. Briefly, the PCR master mix (RealTime Ready Probes Master 2X, Roche Applied Science), 300 nM forward and reverse primers (Eurogentec), 200 nM wild-type and mutant LNA probes (Eurogentec), and diluted PCR amplicons (table e-1) were loaded (1 L/well) in a LightCycler 1536 Multiwell Plate, using the Bravo Automated Liquid Handling Platform (Agilent Technologies). The qPCR cycling conditions on the LightCycler 1536 (Roche Applied Science) were as follows: 96°C for 1 minute, 45 cycles of 95°C for 1 second and 62°C for 25 seconds.
The heatmaps were analyzed using LightCycler 1536 software. For each individual specimen, the percentage of mutant DNA (mutant amplification ratio) was defined as the number of informative wells with mutant probe/number of informative wells with wild-type probe. Investigators were blinded to the result of IDH1 sequencing on tumor DNA.
Statistical analysis. Statistical analysis was performed using
GraphPad 5.0 software. The Mann-Whitney test was used to compare the plasma DNA concentration and the mutant amplification ratio between patient groups. A receiver operating characteristic (ROC) curve was used to assess the accuracy of the mutant amplification ratio in plasma for predicting the presence of the IDH1 R132H mutation in the tumor. A p value Ͻ0.05 was considered significant.
RESULTS Patient characteristics.
A total of 80 patients with gliomas and 31 healthy controls were enrolled, providing a total of 111 collected plasma samples. The characteristics of both the patients with gliomas and healthy controls are summarized in table 1.
DNA extraction from plasma samples. As a preliminary step, a comparison between double and single plasma centrifugation was made. Capillary electrophoresis demonstrated that double centrifugation removes high molecular weight DNA (derived from leukocytes lysis) and allows for a clear visualization of the small-size DNA compared to single centrifugation (figure e-1). We next compared the concentrations of small size DNA obtained after extraction of 1 mL and 4 mL of plasma in 11 patients with voluminous high-grade gliomas. In all cases, extractions from 1 mL of plasma yielded a very small or unde- and C, respectively, p ϭ 0.28). In contrast, in highgrade gliomas, the plasma small size DNA concentration was significantly higher in patients than in healthy controls (figure e-3A, 1.5 ng/mL [range 0.1-50.3] vs 1.2 ng/mL [range 0.1-6.6], p ϭ 0.0045), and the plasma small size DNA concentration increased with enhancing tumor volume (figure e-3B). The DNA concentration was 14.0 ng/mL (range 0.6 -50.3) for enhancing tumor volumes Ն10 cm 3 (group F), compared to 1.6 ng/mL (range 0.4 -24.9) for enhancing tumor volumes Ͻ10 cm 3 (group E, p ϭ 0.008).
Detection of IDH1 R132H mutation in plasma DNA.
Thirty-nine patients (25 with IDH1 R132H glioma and 14 with IDH1 wt glioma) were further analyzed for detection of the IDH1 R132H mutation in the small size DNA extracted from the plasma. Because circulating free DNA is highly contaminated with non-neoplastic DNA, we combined both COLD PCR, which preferentially amplifies mutant DNA, 16 and digital PCR, which is a highly sensitive approach, to detect the IDH1 mutation. The digital PCR conditions were considered valid for a given sample when the total number of amplifications comprised between 100 and 1,200 out of the 1,536 wells of the IDH1 wild-type assay. Figure 1 shows representative heatmaps obtained from an IDH1 wt patient and an IDH1 R132H mutant patient.
The mutant amplification ratio (c.f. supra: the number of informative wells with mutant probe/the number of informative wells with wild-type probe) was 0.16% (95% confidence interval [CI] 0.051-0.268) for the 14 patients with glioma that were IDH1 wt vs 3.2% (95% CI 0.907-5.512) for the 25 patients with glioma that were IDH1 R132H ( p ϭ 0.0096). The area under the ROC curve, which assessed the percentage of mutant DNA, was 0.75 ( figure 2A) . To obtain the required specificity of 100% (95% CI 77%-100%), the highest sensitivity was 60% (95% CI 39%-79%), which corresponded to a positivity threshold of 0.875% for the mutant amplification ratio ( figure 2B ). Under these conditions, the mutation was detected in the plasma DNA of 15 out of 25 patients (60%) harboring an IDH1 R132H mutated tumor and in none of the 14 patients harboring an IDH1 wt tumor (figure 2B, table e-2, figure e-4).
Eight out of 12 low-grade gliomas had the IDH1 R132H mutation (table 3). The mutation was detected in 3 of these (37.5%) plasma small size DNA samples. Interestingly, all of these gliomas had a volume Ͼ22.5 cm 3 (46.7, 96.0, and 174.7 cm 3 ; group C). Among the 27 patients with a high-grade glioma, the mutation was detected in the plasma of 12 out of 17 patients (70.6%) with an IDH1 R132H mutant tumor. Again, the detection rate of the IDH1 R132H mutation in plasma was correlated with the enhancing tumor volume: the IDH1 R132H mutation was not detected in the plasma of the only patient with a nonenhancing tumor (group D). The IDH1 R132H mutation was detected in the plasma of 6/10 (60%) patients in group E (enhancing V Ͻ 10 cm 3 ) and in 6/6 (100%) patients in group F (V Ͼ 10 cm 3 ). All mutant tumors with an enhancing tumor volume higher than 3.5 cm 3 (9/9) were detected in plasma by digital PCR. DISCUSSION We detected small size DNA in the plasma of glioma patients and found that it correlated with grade and contrast-enhancing tumor volume. Most importantly, we were able to detect the IDH1 R132H mutation in the plasma from patients with mutated glioma. The plasma DNA concentrations detected in both healthy subjects and patients with tumors vary considerably from one study to another, 2 which is due, in part, to differences in the methods used to extract and quantify DNA. 17 Performing a second centrifugation reduced contamina-
Figure 1 Representative heatmaps
Representative heatmaps obtained in an IDH1 normal patient (A) and an IDH1 mutant patient (B). Amplification-positive wells appear in green, and negative wells appear in red. For each specimen, the percentage of mutant DNA (mutant amplification ratio) was defined as the number of informative wells (green dots) with a mutant probe/number of informative wells with a wild-type probe. For patient A (nonmutated), the mutant amplification ratio ϭ 0, and for patient B (mutated), the mutant amplification ratio is 23/397 (5.8%). tion of the small size DNA, which mostly arises from tumor cells, with genomic DNA from degraded circulating normal cells (figure e-1), and this explains the lower DNA concentration found here compared with other studies. 6 Patients with high-grade glioma had a significantly higher plasma small size DNA concentration than healthy controls and patients with low-grade glioma. This probably reflects a disruption in the BBB. The intact BBB in low-grade glioma limits the diffusion of small size DNA into the bloodstream and explains the absence of a significant increase in the plasma small size DNA, whereas the disrupted BBB, as evidenced by contrast enhancement in high-grade gliomas, explains the large amount of released small size DNA and its correlation with enhancing tumor volume. High levels of DNA release into the bloodstream may be caused by both apoptosis and necrosis 18, 19 ; however, it is not specific to cancer and may be found in other pathologic conditions such as trauma, inflammatory disease, myocardial infarction, and sepsis. 17 The measurement of free circulating DNA has been proposed for population screening to identify patients with lung cancer. 20 In our series, the specificity of the circulating tumor DNA measurement is too low for population screening, and the plasma DNA concentration in the patients widely overlapped that of the healthy subjects. Identification of the IDH1 R132H mutation in plasma DNA confirms that small size DNA originates from tumor cells. More importantly, because IDH1 mutations are absent in the other intracranial tumors, this result enables the noninvasive diagnosis of gliomas. A major drawback for the detection of a mutation is the dilution of the tumor DNA fragments within the wild-type DNA mixture. COLD PCR is an innovative PCR method that selectively amplifies IDH1 R132H mutated DNA in a background of wild-type DNA. 16 To increase the detection sensitivity, we performed a second round of PCR using digital PCR, which is a highly sensitive technique that allows for the detection of a single mutant DNA copy. 15 The area under the ROC curve (0.75) indicated a powerful association between the percentage of mutant IDH1 R132H detected in the plasma and the presence of the IDH1 R132H mutation in the tumor. We used these data to determine the threshold of positivity for mutant amplification. We prioritized the specificity (which was fixed at 100%) over the sensitivity and deduced from these prerequisites that an amplification ratio Ͼ0.875% (cutoff) indicates an IDH1 R132H mutation (figure 2). With these parameters, the sensitivity was 60% for the whole series, 70% for patients with WHO high-grade gliomas (HGGs), and 100% when considering HGGs with an enhancing tumor volume higher than 3.5 cm 3 .
These data have important practical consequences. First, identification of the IDH1 R132H mutation in plasma small size DNA confirms the diagnosis of glioma in patients who are not amenable to biopsy. The method is highly sensitive in gliomas with large contrast enhancement and is therefore particularly relevant in grade III tumors, which are frequently mutated, compared to primary glioblastomas. The poor sensitivity for mutation detection in small size, low-grade gliomas justifies the development of alternative noninvasive methods for IDH status determination such as 2-hydroxyglutarate detection by magnetic resonance spectroscopy. [21] [22] [23] The next step will be to investigate these methods in patient follow-up for recurrence detection, a switch to malignancy in low-grade gliomas, or differentiating tumor progression from treatment-related effects such as pseudoprogression and radionecrosis. Table 3 IDH1 mutation detection in the plasma according to grade and tumor volume a FLAIR (A, B, C) or T1 postcontrast (D, E, F) volume No. Abbreviation: FLAIR ϭ fluid-attenuated inversion recovery. a IDH1 R132H mutation detection efficiency is more dependent on the volume of the enhancing tumors (groups D, E, and F) than that of the nonenhancing tumors (groups A, B, and C).
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